Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF 77 3-Year EBITDA Growth Rate is 34.00% as of Mar. 2026, which is 963% above its 10-year median of 3.20. GuruFocus rates ALPMF with a GF Score™ of 77/100 and a GF Value™ of $14.36 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Astellas Pharma ranks better than 81.75% on this metric.
During the past 12 months, Astellas Pharma's average EBITDA Per Share Growth Rate was 136.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 34.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Astellas Pharma was 77.50% per year. The lowest was -47.00% per year. And the median was 3.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Astellas Pharma 3-Year EBITDA Growth Rate Related Terms
ALPMF vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 34.00% mean?
Astellas Pharma (ALPMF) has a 3-Year EBITDA Growth Rate of 34.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Astellas Pharma and its competitors. This is 963% above median its historical median of 3.20. According to the industry distribution chart, Astellas Pharma ranks #148 out of 811 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Astellas Pharma's 3-Year EBITDA Growth Rate too high?
Astellas Pharma's current 3-Year EBITDA Growth Rate of 34.00% is 963% above median its 10-year median of 3.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Astellas Pharma's value of 34.00% is 286.4% above this industry median. Based on the distribution chart, Astellas Pharma ranks #148 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #148 out of 811 companies for 3-Year EBITDA Growth Rate. This places Astellas Pharma in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. Astellas Pharma's value of 34.00% is 286.4% above this benchmark. While the company's 10-year median is 3.20 vs. the industry median of 8.80, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current 3-Year EBITDA Growth Rate of 34.00% is 286.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current 3-Year EBITDA Growth Rate is 34.00%, which is 963% above median its own 10-year median of 3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $14.36, compared to a current price of $12.85 — trading 10.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 34.00%, which is 963% above median its 10-year median of 3.20 and 286.4% above the Drug Manufacturers industry median of 8.80. Astellas Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current 3-Year EBITDA Growth Rate is 34.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 10.5% below its estimated GF Value™ of $14.36.
GuruFocus considers Astellas Pharma to be Modestly Undervalued.
Key valuation signals for ALPMF:
3-Year EBITDA Growth Rate: 34.00% (963% above median its 10-year median of 3.20)
GF Value™: $14.36 vs. price of $12.85 (10.5% below fair value)
Industry Position: 286.4% above the Drug Manufacturers median (#148 of 811)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score
Get the complete analysis for ALPMF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
